Targeting KRAS Mutations: A Novel Approach in Advanced NSCLC

home / insights / targeting-kras-mutations-a-novel-approach-in-advanced-nsclc
Current Management of Oncogene-Driven NSCLC

EP. 1: Current Management of Oncogene-Driven NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020
KRAS Mutations in Solid Tumors

EP. 2: KRAS Mutations in Solid Tumors

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020
Testing for KRAS Mutations in NSCLC

EP. 3: Testing for KRAS Mutations in NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020
Counseling Patients With NSCLC When KRAS is Detected

EP. 4: Counseling Patients With NSCLC When KRAS is Detected

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020
Systemic Therapy for KRAS+ Advanced NSCLC

EP. 5: Systemic Therapy for KRAS+ Advanced NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020
Development of KRAS G12C-Targeted Therapy in NSCLC

EP. 6: Development of KRAS G12C-Targeted Therapy in NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020
KRAS G12C Inhibition in Advanced NSCLC: AMG 510

EP. 7: KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020
KRAS G12C Inhibition in Advanced NSCLC: MRTX849

EP. 8: KRAS G12C Inhibition in Advanced NSCLC: MRTX849

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020